Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


China Heparin Industry Report, 2012-2014

NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Heparin Industry Report, 2012-2014
http://www.reportlinker.com/p0354148/China-Heparin-Industry-Report-2012-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

China, abundant in heparin raw materials, has become one of the world's largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, China's export volume of heparin API was no more than 105.2 tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period.

Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend Biochemical Pharmaceutical, which have ranked top 4 industrial players by export for several years in a row, with the combined export value making up more than 70% of China's total export value of heparin. There is no distinct change in terms of the export pattern. However, the export prices of China's top 10 heparin exporters witnessed a downward mobility in 2011-2012H1. Nevertheless, it was not the same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care Article Imp. & Exp. (Group), whose export prices increased by 3.8% and 2.1% year-on-year respectively in Jan.-May, 2012, due to the improved quality of exported products as well as the low cardinal number of exported prices in the preceding year.

Meanwhile, Chinese heparin API flagship enterprises including Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical are projected to expand their capacities and improve the heparin industry chains. Among these tycoons, the first four ones have made IPO, while Nanjing King-Friend Biochemical Pharmaceutical is also preparing for IPO by accepting tutoring. According to public information issued by related enterprises, the heparin API capacity of China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand.

Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in 2011.

However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing. A case in point is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecular weight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, with the sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales of RMB117 million in 2012H1, a year-on-year rise of 237.6%.

Table of Contents
1. Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2. Operating Environment of Chinese Heparin Industry
2.1 Entry Barriers
2.1.1 Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Supply and Demand in Global Market
2.3 Competition in Global Market
2.4 Global Market Forecast

3. Development of Heparin API Industry in China
3.1 Market Status Quo
3.2 Market Supply and Demand
3.3 Competitive Landscape
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Outlook & Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Competition Pattern
4.3 Market Segments
4.3.1 Low Molecular Weight Heparin Preparation
4.3.2 General Heparin Preparation
4.4 Development Outlook & Forecast

5. Key Chinese Heparin Manufacturers
5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Prospects
5.2 Changzhou Qianhong Bio-Pharma Co., Ltd
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Suppliers
5.2.7 Heparin Business
5.2.8 Prospects
5.3 Yantai Dongcheng Biochemicals Co., Ltd
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.6 Clients and Suppliers
5.3.7 Heparin Business
5.3.8 Prospects
5.4 Hebei Changshan Biochemical Pharmaceutical Co., Ltd
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Prospects
5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Prospects
5.6 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
5.6.1 Profile
5.6.2 Operation and Prospects
5.7 Wanbang Biopharmaceuticals
5.7.1 Profile
5.7.2 Operation and Prospects

Selected Charts

Application of Heparin Preparations
Heparin Industry Chain
Difference between Heparin Sodium API and Heparin Standardized Requirements
Heparin Preparation Market Scale and YoY Growth Worldwide, 2006-2011
Performance: Low Molecular Weight Heparin Preparation vs. General Heparin Preparation
Global Heparin Preparation Distribution by Region, 2011
Heparin API Demand and YoY Growth Worldwide, 2007-2011
Sales of Enoxaparin Worldwide by Product, 2010-2012
Regulatory Exclusivity of Lovenox, as of late 2011
Global Heparin Preparation Market Scale, 2011-2014E
Global Heparin API Demand, 2011-2014E
Gross Margin of Major Heparin API Manufacturers in China, 2008-2012
Capacity of Crude Heparin in China, 2009-2011
Average Export Price of Heparin and Heparinate, 2008-2012
Capacity of Major Heparin API Manufacturers in China, as of June 2012
Export Volume and Export Value of Heparin and Heparinate in China, 2008-2012
Export Price of Heparin and Heparinate in China, 2008-2012
Top 10 Export Destinations of Heparin and Heparinate in China by Value, 2011-2012
Top 10 Heparin and Heparinate Enterprises in China by Export Value, 2011
Export Volume and Export Value of Heparin and Heparinate in China, Jan.-May, 2012
Import Volume, Import Value and Unite Price of Heparin and Heparinate in China, 2008-2011
Planned / Ongoing Heparin Sodium API Projects in China, as of June 2012
Heparin Preparation Market Scale and YoY Growth of China, 2007-2011
Market Share of Heparin Preparation Products in China, 2011
Main Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China
Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations
China Low Molecular Weight Heparin Preparation Market Scale, 2009-2011
Purchase Value of Low Molecular Weight Heparin Calcium of Chinese Representative Hospitals, 2010-2011
Low Molecular Weight Heparin Preparation Imported Value of Representative Hospitals in 22 Chinese Cities, 2010-2011
Competition Pattern of China Low Molecular Weight Heparin Calcium Market, 2009
Competition Pattern of China Low Molecular Weight Heparin Sodium Market, 2009
China Heparin Preparation Market Scale and YoY Growth, 2011-2014
Assets and Net Income of Holding Subsidiaries under Hepalink, 2012H1
Revenue and Profit of Hepalink, 2008-2012
Revenue of Hepalink by Product, 2008-2012
Revenue of Hepalink by Region, 2008-2012
Gross Margin of Hepalink by Product, 2008-2012
R&D Investment and Proportion in Revenue of Hepalink, 2009-2011
Revenue of Hepalink from the Top 5 Clients and Proportion, 2008-2012
Revenue and Operating Income of Hepalink, 2011-2014E
Assets, Revenue and Net Income of Subsidiaries under Qianhong Bio-Pharma, 2012H1
Revenue and Profit of Qianhong Bio-Pharma, 2008-2012
Revenue of Qianhong Bio-Pharma by Product, 2008-2012
Revenue of Qianhong Bio-Pharma by Region, 2008-2012
Gross Margin of Qianhong Bio-Pharma by Product, 2008-2012
R&D Investment and Proportion in Revenue of Qianhong Bio-Pharma, 2009-2011
Scheduling of Planned/Ongoing Projects of Qianhong Bio-Pharma, as of June 2012
Top 5 Clients, Revenue Contribution and Proportion of Qianhong Bio-Pharma, 2011
Purchase Value of Qianhong Bio-Pharma's Top 5 Suppliers and Revenue Contribution of Qianhong Bio-Pharma's Top 5 Clients, 2009-2012
Revenue and Gross Margin from Heparin Business of Qianhong Bio-Pharma, 2008-2012
Revenue and Operating Income of Qianhong Bio-Pharma, 2011-2014
Assets, Revenue and Net Income of Subsidiaries under Dongcheng Biochemicals, 2012H1
Revenue and Profit of Dongcheng Biochemicals, 2008-2012
Revenue of Dongcheng Biochemicals by Product, 2008-2012
Revenue of Dongcheng Biochemicals by Region, 2008-2012
Gross Margin of Dongcheng Biochemicals by Product, 2008-2012
R&D Investment and Proportion in Revenue of Dongcheng Biochemicals, 2008-2012
Revenue and Gross Margin from Heparin Sodium API Business of Dongcheng Biochemicals, 2008-2012
Heparin Sodium API Price of Dongcheng Biochemicals, 2009-2011
Revenue Contribution of Dongcheng Biochemicals' Top 5 Heparin Sodium API Clients, 2009-2011
Scheduling of Heparin Sodium API Projects of Dongcheng Biochemicals, 2013-2015E
Revenue and Profit of Dongcheng Biochemicals, 2011-2014E
Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2008-2012
Revenue of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012
Revenue of Hebei Changshan Biochemical Pharmaceutical by Region, 2008-2012
Gross Margin of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012
R&D Investment and Proportion in Revenue of Hebei Changshan Biochemical Pharmaceutical, 2009-2011
Product Research Scheduling of Hebei Changshan Biochemical Pharmaceutical, as of late 2011
Name List, Revenue Contribution and Proportion of Top 5 Clients of Hebei Changshan Biochemical Pharmaceutical, 2011
Heparin Product Certificates Won by Hebei Changshan Biochemical Pharmaceutical Overseas, as of late 2011
Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2011-2014E
Revenue and Profit of Tianjin Chase Sun Pharmaceutical, 2008-2012
Revenue of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012
Revenue of Tianjin Chase Sun Pharmaceutical by Region, 2008-2012
Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012
R&D Investment and Proportion in Revenue of Tianjin Chase Sun Pharmaceutical, 2009-2011
Name List, Revenue Contribution and Proportion of Top 5 Clients of Tianjin Chase Sun Pharmaceutical, 2011
Name List, Purchase Value and Proportion of Top 5 Suppliers of Tianjin Chase Sun Pharmaceutical, 2011
Revenue and Gross Margin from Heparin Business of Tianjin Chase Sun Pharmaceutical, 2008-2012
Revenue and Operating Income of Tianjin Chase Sun Pharmaceutical, 2011-2014
Assets and Net Income of Wanbang Biopharmaceuticals, 2008-2011


To order this report:
Pharmaceutical Industry:
China Heparin Industry Report, 2012-2014

__________________________
Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
VisionMobile recently published one of the best reports on apps for vehicles that I have read. It is frustrating with how difficult it is to actually get an app approved for use in a car. Here are some of the unique challenges: Safety first considerations (like driver distraction) Lo...
Clearly, the buzz around wearable technology has to do with the hands-free user design – these smart peripherals allow for a better experience for certain functions. While consumers are not going to do away with their iPhones, tablets and computers anytime soon, wearables make sense as...
There are a variety of opinions on the seriousness of Heartbleed being put forth ranging from "it's not the end of the world" to "the sky is falling, duck and cover." Usually the former cites the relatively low percentage of sites impacted by Heartbleed, pegged at about 17% or 500,000 ...
HTML5 is still one of the most discussed topics amongst us technical types. The key challenge, however, has remained unanswered for a long time. How do you effectively wrap HTML5 for use in native mobile applications? Unfortunately I do not have a universal answer, but I do have a s...
If the CEO of the company has anything to say about Lenovo's standing in the PC industry, the company won't stop until massive growth is achieved. In a series of recent buying sweeps, Lenovo has bought Motorola Mobility for a whopping $2.91 billion from Google and also acquired the ser...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE